Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions
Executive Summary
The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.
You may also be interested in...
505(b)(2)-Like Pathway For Biologics May Gain Renewed Interest With Senate User Fee Bill Pending
Draft legislative text would allow some biologics and biosimilars to rely on published literature or other information and avoid some clinical studies, but the wide FDA discretion also included could raise more questions.
505(b)(2)-Like Pathway For Biologics May Gain Renewed Interest With Senate User Fee Bill Pending
Draft legislative text would allow some biologics and biosimilars to rely on published literature or other information and avoid some clinical studies, but the wide FDA discretion also included could raise more questions.
House User Fee Mark-Up: Few Tweaks, But Concerns About ALS And Accelerated Approval
Clinical trial diversity, FDA hiring authority, and inactive ingredient disclosure provisions all get slight modifications. The bill glides through committee, but not without some complaints about agency performance.